|
1
|
Boyle P: Triple-negative breast cancer:
epidemiological considerations and recommendations. Ann Oncol.
23:(Suppl 6). vi7–vi12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Gruppo Italiano Malattie Ematologiche dellAdulto;
German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance
Leukemia: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chambon P: A decade of molecular biology
of retinoic acid receptors. FASEB J. 10:940–954. 1996.PubMed/NCBI
|
|
4
|
Germain P, Chambon P, Eichele G, Evans RM,
Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ and
Gronemeyer H: International Union of Pharmacology. LXIII. Retinoid
X receptors. Pharmacol Rev. 58:760–772. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koeffler HP: Is there a role for
differentiating therapy in non-APL AML? Best Pract Res Clin
Haematol. 23:503–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Donato LJ, Suh JH and Noy N: Suppression
of mammary carcinoma cell growth by retinoic acid: the cell cycle
control gene Btg2 is a direct target for retinoic acid receptor
signaling. Cancer Res. 67:609–615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Altucci L, Rossin A, Raffelsberger W,
Reitmair A, Chomienne C and Gronemeyer H: Retinoic acid-induced
apoptosis in leukemia cells is mediated by paracrine action of
tumor-selective death ligand TRAIL. Nat Med. 7:680–686. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donato LJ and Noy N: Suppression of
mammary carcinoma growth by retinoic acid: proapoptotic genes are
targets for retinoic acid receptor and cellular retinoic
acid-binding protein II signaling. Cancer Res. 65:8193–8199. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kitareewan S, Pitha-Rowe I, Sekula D,
Lowrey CH, Nemeth MJ, Golub TR, Freemantle SJ and Dmitrovsky E:
UBE1L is a retinoid target that triggers PML/RARalpha degradation
and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci
USA. 99:3806–3811. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schug TT, Berry DC, Shaw NS, Travis SN and
Noy N: Opposing effects of retinoic acid on cell growth result from
alternate activation of two different nuclear receptors. Cell.
129:723–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schug TT, Berry DC, Toshkov IA, Cheng L,
Nikitin AY and Noy N: Overcoming retinoic acid-resistance of
mammary carcinomas by diverting retinoic acid from PPARbeta/delta
to RAR. Proc Natl Acad Sci USA. 105:7546–7551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan NS, Shaw NS, Vinckenbosch N, Liu P,
Yasmin R, Desvergne B, Wahli W and Noy N: Selective cooperation
between fatty acid binding proteins and peroxisome
proliferator-activated receptors in regulating transcription. Mol
Cell Biol. 22:5114–5127. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di-Poï N, Tan NS, Michalik L, Wahli W and
Desvergne B: Antiapoptotic role of PPARbeta in keratinocytes via
transcriptional control of the Akt1 signaling pathway. Mol Cell.
10:721–733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolf G: Cellular retinoic acid-binding
protein II: a coactivator of the transactivation by the retinoic
acid receptor complex RAR. RXR. Nutr Rev. 58:151–153. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Metwally TH, Hussein MR, Pour PM,
Kuszynski CA and Adrian TE: Natural retinoids inhibit proliferation
and induce apoptosis in pancreatic cancer cells previously reported
to be retinoid resistant. Cancer Biol Ther. 4:474–483. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Metwally TH, Hussein MR, Pour PM,
Kuszynski CA and Adrian TE: High concentrations of retinoids induce
differentiation and late apoptosis in pancreatic cancer cells in
vitro. Cancer Biol Ther. 4:602–611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vreeland AC, Levi L, Zhang W, Berry DC and
Noy N: Cellular retinoic acid-binding protein 2 inhibits tumor
growth by two distinct mechanisms. J Biol Chem. 289:34065–34073.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Favorskaya I, Kainov Y, Chemeris G,
Komelkov A, Zborovskaya I and Tchevkina E: Expression and clinical
significance of CRABP1 and CRABP2 in non-small cell lung cancer.
Tumour Biol. 35:10295–10300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Passeri D, Doldo E, Tarquini C, Costanza
G, Mazzaglia D, Agostinelli S, Campione E, Di Stefani A, Giunta A,
Bianchi L, et al: Loss of CRABP-II characterizes human skin poorly
differentiated squamous cell carcinomas and favors DMBA/TPA-induced
carcinogenesis. J Invest Dermatol. 136:1255–1266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gupta S, Pramanik D, Mukherjee R, Campbell
NR, Elumalai S, de Wilde RF, Hong SM, Goggins MG, De Jesus-Acosta
A, Laheru D, et al: Molecular determinants of retinoic acid
sensitivity in pancreatic cancer. Clin Cancer Res. 18:280–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albino-Sanchez ME, Vazquez-Hernandez J,
Ocadiz-Delgado R, Serafin-Higuera N, León-Galicia I, Garcia-Villa
E, Hernandez-Pando R and Gariglio P: Decreased RARβ expression
induces abundant inflammation and cervical precancerous lesions.
Exp Cell Res. 346:40–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang A, Wang X, Shan X, Li Y, Wang P,
Jiang P and Feng Q: Curcumin reactivates silenced tumor suppressor
gene RARβ by reducing DNA methylation. Phytother Res. 29:1237–1245.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu XC: Tumor-suppressive activity of
retinoic acid receptor-beta in cancer. Cancer Lett. 253:14–24.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darwiche N, Celli G, Tennenbaum T, Glick
AB, Yuspa SH and De Luca LM: Mouse skin tumor progression results
in differential expression of retinoic acid and retinoid X
receptors. Cancer Res. 55:2774–2782. 1995.PubMed/NCBI
|
|
25
|
Xu XC, Wong WY, Goldberg L, Baer SC, Wolf
JE, Ramsdell WM, Alberts DS, Lippman SM and Lotan R: Progressive
decreases in nuclear retinoid receptors during skin squamous
carcinogenesis. Cancer Res. 61:4306–4310. 2001.PubMed/NCBI
|
|
26
|
Brigger D, Schläfli AM, Garattini E and
Tschan MP: Activation of RARα induces autophagy in SKBR3 breast
cancer cells and depletion of key autophagy genes enhances ATRA
toxicity. Cell Death Dis. 6:e18612015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tomita A, Kiyoi H and Naoe T: Mechanisms
of action and resistance to all-trans retinoic acid (ATRA)
and arsenic trioxide (As2O3) in acute
promyelocytic leukemia. Int J Hematol. 97:717–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Applegate CC and Lane MA: Role of
retinoids in the prevention and treatment of colorectal cancer.
World J Gastrointest Oncol. 7:184–203. 2015.PubMed/NCBI
|
|
29
|
Ak T and Gülçin I: Antioxidant and radical
scavenging properties of curcumin. Chem Biol Interact. 174:27–37.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Joe B, Vijaykumar M and Lokesh BR:
Biological properties of curcumin-cellular and molecular mechanisms
of action. Crit Rev Food Sci Nutr. 44:97–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Yu J, Cui R, Lin J and Ding X:
Curcumin in treating breast cancer (Review). J Lab Autom.
21:723–731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bimonte S, Barbieri A, Leongito M,
Piccirillo M, Giudice A, Pivonello C, de Angelis C, Granata V,
Palaia R and Izzo F: Curcumin anticancer studies in pancreatic
cancer. Nutrients. 8:82016. View Article : Google Scholar :
|
|
33
|
Jordan BC, Mock CD, Thilagavathi R and
Selvam C: Molecular mechanisms of curcumin and its semisynthetic
analogues in prostate cancer prevention and treatment. Life Sci.
152:135–144. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Howells LM, Mahale J, Sale S, McVeigh L,
Steward WP, Thomas A and Brown K: Translating curcumin to the
clinic for lung cancer prevention: evaluation of the preclinical
evidence for its utility in primary, secondary, and tertiary
prevention strategies. J Pharmacol Exp Ther. 350:483–494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chainani-Wu N: Safety and
anti-inflammatory activity of curcumin: a component of tumeric
(Curcuma longa). J Altern Complement Med. 9:161–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheah YH, Nordin FJ, Sarip R, Tee TT,
Azimahtol HL, Sirat HM, Rashid BA, Abdullah NR and Ismail Z:
Combined xanthorrhizol-curcumin exhibits synergistic growth
inhibitory activity via apoptosis induction in human breast cancer
cells MDA-MB-231. Cancer Cell Int. 9:12009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Javvadi P, Segan AT, Tuttle SW and
Koumenis C: The chemopreventive agent curcumin is a potent
radiosensitizer of human cervical tumor cells via increased
reactive oxygen species production and overactivation of the
mitogen-activated protein kinase pathway. Mol Pharmacol.
73:1491–1501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anitha A, Maya S, Deepa N, Chennazhi KP,
Nair SV and Jayakumar R: Curcumin-loaded N,O-carboxymethyl chitosan
nanoparticles for cancer drug delivery. J Biomater Sci Polym Ed.
23:1381–1400. 2012.PubMed/NCBI
|
|
39
|
Mukerjee A and Vishwanatha JK:
Formulation, characterization and evaluation of curcumin-loaded
PLGA nanospheres for cancer therapy. Anticancer Res. 29:3867–3875.
2009.PubMed/NCBI
|
|
40
|
Ma Z, Haddadi A, Molavi O, Lavasanifar A,
Lai R and Samuel J: Micelles of poly(ethylene
oxide)-b-poly(epsilon-caprolactone) as vehicles for the
solubilization, stabilization, and controlled delivery of curcumin.
J Biomed Mater Res A. 86:300–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bordoloi D, Roy NK, Monisha J, Padmavathi
G and Kunnumakkara AB: Multi-targeted agents in cancer cell
chemosensitization: what we learnt from curcumin thus far. Recent
Patents Anticancer Drug Discov. 11:67–97. 2016. View Article : Google Scholar
|
|
42
|
Saha S, Adhikary A, Bhattacharyya P, Das T
and Sa G: Death by design: where curcumin sensitizes drug-resistant
tumours. Anticancer Res. 32:2567–2584. 2012.PubMed/NCBI
|
|
43
|
Chen P, Li J, Jiang HG, Lan T and Chen YC:
Curcumin reverses cisplatin resistance in cisplatin-resistant lung
caner cells by inhibiting FA/BRCA pathway. Tumour Biol.
36:3591–3599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Toden S, Okugawa Y, Jascur T, Wodarz D,
Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A:
Curcumin mediates chemosensitization to 5-fluorouracil through
miRNA-induced suppression of epithelial-to-mesenchymal transition
in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thulasiraman P, McAndrews DJ and
Mohiudddin IQ: Curcumin restores sensitivity to retinoic acid in
triple negative breast cancer cells. BMC Cancer. 14:7242014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou B, Huang J, Zuo Y, Li B, Guo Q, Cui
B, Shao W, Du J and Bu X: 2a, a novel curcumin analog, sensitizes
cisplatin-resistant A549 cells to cisplatin by inhibiting
thioredoxin reductase concomitant oxidative stress damage. Eur J
Pharmacol. 707:130–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jiang M, Huang O, Zhang X, Xie Z, Shen A,
Liu H, Geng M and Shen K: Curcumin induces cell death and restores
tamoxifen sensitivity in the antiestrogen-resistant breast cancer
cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. 18:701–720. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2[-Delta Delta C(T)] method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu RZ, Graham K, Glubrecht DD, Germain
DR, Mackey JR and Godbout R: Association of FABP5 expression with
poor survival in triple-negative breast cancer: implication for
retinoic acid therapy. Am J Pathol. 178:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Prasad NR, Muthusamy G, Shanmugam M and
Ambudkar SV: South Asian medicinal compounds as modulators of
resistance to chemotherapy and radiotherapy. Cancers (Basel).
8:82016. View Article : Google Scholar :
|
|
51
|
Montgomery A, Adeyeni T, San K, Heuertz RM
and Ezekiel UR: Curcumin sensitizes silymarin to exert synergistic
anticancer activity in colon cancer cells. J Cancer. 7:1250–1257.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
de Ruiz Porras V, Bystrup S,
Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuji
C, Manzano JL, Layos L, et al: Curcumin mediates
oxaliplatin-acquired resistance reversion in colorectal cancer cell
lines through modulation of CXC-chemokine/NF-κB signalling pathway.
Sci Rep. 6:246752016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Selvendiran K, Ahmed S, Dayton A,
Kuppusamy ML, Rivera BK, Kálai T, Hideg K and Kuppusamy P: HO-3867,
a curcumin analog, sensitizes cisplatin-resistant ovarian
carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Cancer Biol Ther. 12:837–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chanvorachote P, Pongrakhananon V,
Wannachaiyasit S, Luanpitpong S, Rojanasakul Y and Nimmannit U:
Curcumin sensitizes lung cancer cells to cisplatin-induced
apoptosis through superoxide anion-mediated Bcl-2 degradation.
Cancer Invest. 27:624–635. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
di Masi A, Leboffe L, De Marinis E, Pagano
F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P and Nervi C:
Retinoic acid receptors: from molecular mechanisms to cancer
therapy. Mol Aspects Med. 41:1–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Flamini MI, Gauna GV, Sottile ML, Nadin
BS, Sanchez AM and Vargas-Roig LM: Retinoic acid reduces migration
of human breast cancer cells: role of retinoic acid receptor beta.
J Cell Mol Med. 18:1113–1123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen CF, Goyette P and Lohnes D: RARgamma
acts as a tumor suppressor in mouse keratinocytes. Oncogene.
23:5350–5359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hatoum A, El-Sabban ME, Khoury J, Yuspa SH
and Darwiche N: Overexpression of retinoic acid receptors alpha and
gamma into neoplastic epidermal cells causes retinoic acid-induced
growth arrest and apoptosis. Carcinogenesis. 22:1955–1963. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shehzad A, Wahid F and Lee YS: Curcumin in
cancer chemoprevention: molecular targets, pharmacokinetics,
bioavailability, and clinical trials. Arch Pharm (Weinheim).
343:489–499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ramachandran C, Rodriguez S, Ramachandran
R, Nair Raveendran PK, Fonseca H, Khatib Z, Escalon E and Melnick
SJ: Expression profiles of apoptotic genes induced by curcumin in
human breast cancer and mammary epithelial cell lines. Anticancer
Res. 25:3293–3302. 2005.PubMed/NCBI
|
|
61
|
Van Erk MJ, Teuling E, Staal YC, Huybers
S, Van Bladeren PJ, Aarts JM and Van Ommen B: Time- and
dose-dependent effects of curcumin on gene expression in human
colon cancer cells. J Carcinog. 3:82004. View Article : Google Scholar : PubMed/NCBI
|
